

Bod Science Limited receives \$1.512 million R&D Tax Rebate

- \$1.512 million Research and Development (R&D) Tax Incentive Rebate received for 2022 financial year
- Funds received reflective of Bod's commitment and investment in Research and Development (R&D)

Sydney, Australia – 20 December 2022: Cannabis focused drug development and product innovation company Bod Science Limited ("Bod" or "the Company") (ASX: BOD) is pleased to advise it has received a \$1.512 million Research and Development (R&D) Tax Incentive Rebate for the 2022 financial year.

The rebate relates to applicable R&D activities conducted by Bod during the 2022 financial year, including 11 R&D Programs – 3 in phase I and II trials, and 8 in pre-clinical.

The rebate underscores Bod's commitment to drug development and product innovation including its' ongoing clinical trial of a unique Schedule 3 (Pharmacist Only) CBD medicine which Bod has exclusively licensed under a five year supply agreement to Australia's largest generic pharmaceutical and private label OTC medicines company, Arrotex Pharmaceuticals (refer ASX announcement 2 December 2022).

Management commentary:

CEO Ms Jo Patterson said: *"Bod continues to prioritise strategic investment in rigorous scientific research and development. This substantial R&D tax rebate is reflective of Bod's commitment to, and strong track record of partnerships with leaders in R&D."*

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research organisations to advance the use of Cannabis related products with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033